Fecal Calprotectin: Validation as a Noninvasive Measure of Bowel Inflammation in Childhood Inflammatory Bowel Disease

Bunn, S. K.; Bisset, W M; Main, Margaret Jessie Campbell; Gray, Elizabeth; Olson, Shona; Golden, Barbara E.

doi:10.1097/00005176-200107000-00003

Cited by 210 publications

(194 citation statements)

References 33 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Other than routine laboratory tests as noted above, there are fecal markers, such as calprotectin and lactoferrin, and serological markers, such as ASCA and pANCA, that may aid in the differential diagnosis. Earlier reports demonstrated that fecal calprotectin correlated closely with the best invasive measures of colonic and small bowel inflammation in childhood inflammatory bowel disease and lends itself particularly to the monitoring and assessment of therapeutic interventions in children with inflammatory bowel disease [21] . Subsequent experience with calprotectin has yielded similar findings and in some practices is used frequently to differentiate functional from inflammatory GI disorders.…”

Section: Diagnosismentioning

confidence: 82%

Special issues in pediatric inflammatory bowel disease

Dubinsky¹

2007

WJG

View full text Add to dashboard Cite

The incidence of pediatric inflammatory bowel disease (IBD) is rising and recent advances in diagnostics and therapeutics have improved the care provided to these children. There are distinguishing features worth noting between early onset and adult onset IBD. Physical and psychosocial development remains a critical target for the comprehensive management of pediatric IBD. Children are not just little adults and consideration must be given to the stages of development and how these stages impact disease presentation and management. The final stage will be the transition from pediatric care to that of adult oriented care and special consideration must be given to make this a successful process. This review highlights special considerations in the management of the child with IBD.

show abstract

Section: Diagnosismentioning

confidence: 82%

Special issues in pediatric inflammatory bowel disease

Dubinsky¹

2007

WJG

View full text Add to dashboard Cite

show abstract

“…However, not all of the included studies were of newly presenting patients. Bunn et al 71 had more patients with confirmed IBD than new patients. Kolho et al 72 enrolled a group of newly presenting patients but only 30 of the 132 stool samples were taken at presentation, with others being taken after treatment, as long as 72 weeks later.…”

Section: Results Of Clinical Effectiveness Reviewmentioning

confidence: 99%

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

225

198

View full text Add to dashboard Cite

“…Increased calprotectin concentrations that correlated with the endoscopic-histological grading of intestinal inflammation were detected in adults and children with inflammatory bowel diseases (IBD). [3][4][5] Faecal concentrations of calprotectin were higher in subjects with colorectal carcinoma and in those on short-term anti-inflammatory treatment than in healthy controls. 6,7 In addition, the combination of faecal calprotectin, intestinal permeability test and positive Rome I criteria reliably discriminated between patients with organic and nonorganic intestinal diseases.…”

Section: Introductionmentioning

confidence: 98%

Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration

Bruzzese

Raia

Gaudiello

et al. 2004

Aliment Pharmacol Ther

163

121

View full text Add to dashboard Cite

Summary Aims : To assess the incidence of intestinal inflammation in children with cystic fibrosis and to investigate whether probiotics decrease it. Study design : In this two‐phase, controlled, prospective study, faecal calprotectin was measured by enzyme‐linked immunosorbent assay in 30 children with cystic fibrosis, 30 healthy controls and 15 children with active inflammatory bowel disease. Ten children with cystic fibrosis received Lactobacillus GG, and faecal calprotectin was re‐measured 4 weeks later. Rectal nitric oxide production was measured with the rectal dialysis bag technique in 20 children with cystic fibrosis, 20 healthy controls and 15 children with inflammatory bowel disease. Five children with cystic fibrosis received Lactobacillus GG and nitric oxide was re‐measured 4 weeks later. Results : Mean faecal calprotectin was significantly higher in the two groups of patients than in controls. Abnormal values were detected in 27 of 30 cystic fibrosis and in 15 of 15 inflammatory bowel disease children. Also mean nitric oxide production was increased in both group of patients, and abnormal values were detected in 19 of 20 cystic fibrosis and in 15 of 15 inflammatory bowel disease children. Calprotectin and nitric oxide concentrations were reduced after probiotics administration. Conclusions : Intestinal inflammation is a major feature of cystic fibrosis and is reduced by probiotics. The latter finding suggests that intestinal microflora play a major role in intestinal inflammation in cystic fibrosis children.

show abstract

Fecal Calprotectin: Validation as a Noninvasive Measure of Bowel Inflammation in Childhood Inflammatory Bowel Disease

Cited by 210 publications

References 33 publications

Special issues in pediatric inflammatory bowel disease

Special issues in pediatric inflammatory bowel disease

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration

Contact Info

Product

Resources

About